
Jevtana60 mg/1.5
Synovia Pharma PLC
Cabazitaxel is an antineoplastic (anticancer) taxane medicine used in oncology.
Cabazitaxel is an antineoplastic (anticancer) taxane medicine used in oncology.
| Regimen | Dose | Frequency | Companion therapy |
|---|---|---|---|
| Standard | 20 mg/m² IV infusion over 1 hour | Every 3 weeks | Oral prednisone/prednisolone 10 mg once daily throughout treatment |
| Selected patients (per specialist assessment) | 25 mg/m² IV infusion over 1 hour | Every 3 weeks | Oral prednisone/prednisolone 10 mg once daily throughout treatment |
Treatment should not be initiated if the neutrophil count is at or below the safety threshold (≤1,500 cells/mm³); blood counts must be checked before every cycle and regularly (e.g. weekly during cycle 1).
At least 30 minutes before every infusion of Cabazitaxel, patients should receive premedication with an antihistamine, a corticosteroid (e.g. dexamethasone), and an H2-receptor antagonist, to reduce the risk of hypersensitivity reactions - this is particularly important before the first two infusions.
| Hepatic function | Recommended dose |
|---|---|
| Mild impairment | 20 mg/m² |
| Moderate impairment | 15 mg/m² |
| Severe impairment | Contraindicated - see Contraindications |
Dose delay and/or reduction (e.g. from 25 mg/m² to 20 mg/m², or from 20 mg/m² to 15 mg/m²) is required for prolonged severe neutropenia, febrile neutropenia, severe (grade ≥3) diarrhoea, or grade 2 or worse peripheral neuropathy, per the treating oncologist's protocol; treatment is discontinued for severe peripheral neuropathy. See Precautions and Warnings for boxed-warning detail on neutropenia.
If a strong CYP3A inhibitor cannot be avoided, a dose reduction of approximately 25% for Cabazitaxel should be considered - see Interactions.
| System | Effect |
|---|---|
| Blood | Neutropenia, anaemia, leukopenia (often severe and requiring monitoring - see Precautions) |
| Gastrointestinal | Diarrhoea, nausea, vomiting, constipation, abdominal pain, decreased appetite |
| General | Fatigue, asthenia (weakness), back pain |
| Urinary | Haematuria (blood in urine) |
Patients should contact their treating oncology team immediately if fever, signs of infection, severe diarrhoea, breathing difficulty, or unusual bleeding/bruising occur.
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.